Active, Not Recruiting
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
NCT06780930
- Conditions
- Residual or Recurrent Grade 2 IDH Mutant Glioma
- Locations
-
- The Second People's Hospital of Shenzhen Shenzhen, Guangdong, China
- West China Hospital Sichuan University Chengdu, Sichuan, China
- Tiantan Hospital Beijing, China
- Sanbo Brain Hospital, Capital Medical University Beijing, China